CURRENT SCIENCE REVIEWS By Joe Bruman February 1998 Page 1 of 3 Antonini A et al; Brain 1997;120:2187-2195: They used PET scans with two different markers, Fluorodopa and Raclopride, on 10 PD patients, 9 with MSA, and 30 controls, to look for diagnostic distinction between MSA and PD. The fluorodopa scans showed disease but didn't differentiate, while raclopride (radioactive C to measure glucose metabolism) was successful. Moeller J, Eidelberg D; Brain 1997;120:2197-2206: The substantia nigra degenerates both in PD and in normal aging, but the detailed patterns of degeneration differ. They studied 37 PD patients and 20 normal controls using PET and the glucose marker fluorodeoxyglucose and found that PD doesn't simply accelerate the aging process, it alters the pattern. By extrapolating backward from the measured patterns, they also suggest that PD has a fairly short preclinical (latent) period of about 4.5 years. van Elst L et al; Brain 1997;120:2219-2228: Vision defects are common in PD. Presenting calibrated (grid) stimuli to 27 PD patients, 6 with MSA, and 27 healthy controls showed that the PD group had less contrast sensitivity than the others. Authors speculate that the loss is mediated by retinal effects, and that it may help in differential diagnosis. Sedek G et al; Clin Neuropharm 1997;20:531-541: In a dosage tolerance and safety test, they gave various doses of Sinemet and tolcapone to 20 healthy volunteers, finding that the optimum dose of tolcapone about doubled the half-life of levodopa. Miyawaki E et al; Clin Neuropharm 1997;20:523-530: They tracked 811 levodopa-responsive PD patients for up to 15 years, for motor complications ascribed to chronic levodopa therapy, including "wearing off" and sudden unpredictable "off" effects, concluding that they become more common with duration, although some patients stayed complication-free into the second decade of the disease. Oakes D; Clin Neuropharm 1997;20:342: The somewhat rancorous debate over selegiline goes on. The author here rebuts a prior argument (CSR Sep 97) about proper treatment of statistical mortality data. Beijjani B et al; Neur 1997;49:1564-1569: The probe used for Deep-Brain Stimulation (DBS) has a choice of four stimulation sites along its length, allowing a comparison after the implantation is complete. Stimulation at the top (dorsal) surface of the pallidum had effect strikingly different from stimulation at the lower (posteroventral) surface. Current functional models of the basal ganglia don't explain paradoxical effects of either pallidotomy or DBS; for example, how levodopa-induced dyskinesia (LID) can be suppressed simultaneously with improvement of classic PD signs; and authors suggest maybe different neuroanatomic systems are involved. Churchyard A et al; Neur 1997;49:1570-1576: Severe dementia affects 10% to 20% of PD patients, usually after age 65. Postmortem study of 27 PD patients and 11 controls, who had been previously examined for cognitive impairment, showed more frequent anomalies (Lewy bodies, plaques, tangles, etc,) in the hippocampus of PD patients who had been demented. CURRENT SCIENCE REVIEWS By Joe Bruman February 1998 p. 2 of 3 Leighton W et al; Neur 1997;49:1577-1579: Certain mutations of the dopamine transporter (DAT) gene are prime suspects in PD, since DAT is involved with presynaptic uptake of dopamine in the substantia nigra, and a strong correlation was previously found in a cohort of Caucasians. However, in a sample of 203 PD patients and 230 healthy controls of Chinese descent, no such association of the most common mutation was found. Bennett D et al; Neur 1997;49:1580-1587: After a structured training protocol three nurse clinicians, along with a neurologist, administered a modified Unified Parkinson's Disease Rating Scale (UPDRS) to 75 older subjects, and the agreement of results shows that with such training, nurse clinicians are competent to administer the scale. Bonuccelli U et al; Neur 1997;49:1587-1590: A double-blind test of clozapine, both acute and chronic, on 17 PD patients with mixed (resting and/or postural) levodopa-resistant tremor showed that it is effective for at least 15 months. Authors therefore suggest that in such cases clozapine should be tried first, before resorting to thalamotomy or VIM stimulation. Biousse V et al; Neur 1998;50:258-265: Proximity of the optic tract to the currently preferred lesion site for pallidotomy in PD carries the risk of vision impairment if the location is inaccurate. Experience with 40 such operations showed that microelectrode recording (monitoring localized response or response to localized stimuli) is a safe and effective means of ensuring accurate placement of the lesioning probe, even if the optic tract itself is used as a guide. Ondo W et al; Neur 1998;50:266-270: Application of the Unified Parkinson's Disease Rating Scale (UPDRS) to 34 consecutive PD pallidotomy recipients, immediately before and 3 months after the procedure, showed that unilateral pallidotomy is safe and effective against PD motor symptoms, often bilaterally. Kobayashi T et al; Ann Neur 1998;43:120-123: Genetic comparison of 176 confirmed PD patients with 223 healthy controls revealed a significant association of PD with mutation of the gene encoding the "E2 subunit of the alpha-ketoglutarate dehydrogenase complex". Guang-xi Z et al; J Neur N'surg Psych 1997;63:754-758: Analysis of cerebrospinal fluid (CSF) from 23 PD patients, 8 with peripheral neuropathy but not PD, and 12 healthy controls showed that concentration of beta-phenylethylamine (PEA) is depressed in the cerebrospinal fluid (CSF) of PD patients. Evidente V, Gwinn K; J Neur N'surg Psych 1998;64:5: Many survivors of the 1915-35 encephalitis pandemic developed parkinsonism several years after recovery. Old photos of one such victim show the familiar rigid stance, stooped posture, bent knees, blank expression, and arms stiffly fixed at sides. CURRENT SCIENCE REVIEWS By Joe Bruman February 1998 p. 3 of 3 Tsai C et al; J Neur N'surg Psych 1998;64:33-36: Transcranial magnetic stimuli delivered over the motor cortex of two patients with primary orthostatic tremor briefly suppressed it, suggesting that a central oscillator involving the motor cortex plays a crucial role in either generation or modulation of such tremor. Meco G et al; J Neur N'surg Psych 1998;64:135: Risperidone, a new atypical antipsychotic with potent serotonin-S2 and secondary dopamine-D2 antagonist properties, was given to 8 PD patients suffering levodopa-induced dyskinesia (LID). Besides its neuroleptic effect it markedly reduced LID, during followups for as long as 21 months. Mesholam R et al; Arch Neur 1998;55:84-90: They compared data from 43 previously published reports about anosmia (loss of smell sense) in Alzheimer's and Parkinson's, concluding that the loss is acute in both diseases, but not different. They speculate about use for preclinical diagnosis. J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013